MSLENasdaqPharmaceutical PreparationsFiscal year ends December 31
Satellos Bioscience Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 27, 2026
$6.44−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Satellos Bioscience has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Satellos Bioscience filed with the SEC
Satellos Granted Composition of Matter Patent for Forazapadin
EX-99.1 to Form 6-K
Satellos to Present at the 31st Annual Congress of the World Muscle Society
EX-99.1 to Form 6-K
Satellos to Participate in Upcoming Investor Conferences
EX-99.1 to Form 6-K
1301 Avenue of the Americas, 5 th Floor
EX-99.1 to Form 6-K
Condensed Consolidated Interim Financial Statements
EX-99.1 to Form 6-K
For the three months and six months ended June 30, 2026, and 2025
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Satellos to Present Clinical Program Updates at ICNMD 2026
EX-99.1 to Form 6-K
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
EX-99.1 to Form 6-K
In accordance with Section 11.3 of National Instrument 51-102, the following
EX-99.1 to Form 6-K
Satellos to Participate in Upcoming Investor Conferences
EX-99.1 to Form 6-K
NOTICE OF MEETING AND MANAGEMENT INFORMATION CIRCULAR RELATING TO THE
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Condensed Consolidated Interim Financial Statements
EX-99.1 to Form 6-K
For the three months ended March 31, 2026, and 2025
EX-99.2 to Form 6-K
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
EX-99.1 to Form 6-K
Satellos Announces Upcoming Oral and Poster Presentations at the
EX-99.1 to Form 6-K
to Participate in Upcoming Investor Conferences
EX-99.1 to Form 6-K
to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
EX-99.1 to Form 6-K
Name and Address of Company
EX-99.1 to Form 6-K
Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
EX-99.1 to Form 6-K
Satellos to Participate in the Guggenheim
EX-99.1 to Form 6-K
Pre-Funded Warrants to Purchase up to 495,049 Common
EX-99.1 to Form 6-K
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON
EX-99.2 to Form 6-K
Satellos Announces Launch of Public
EX-99.3 to Form 6-K